Видео ютуба по тегу Medicines: Ulotaront

Clinical Trial: SEP-363856 75mg for Schizophrenia (NCT04092686)
Clinical Trial: SEP-363856 75mg for Schizophrenia (NCT04092686)
APA House Call: SEP-363856 for Schizophrenia
APA House Call: SEP-363856 for Schizophrenia
New Treatment For Schizophrenia Drug | Mark Agresti
New Treatment For Schizophrenia Drug | Mark Agresti
What is a trace amine-associated receptor 1 agonist? Can we treat schizophrenia with it?
What is a trace amine-associated receptor 1 agonist? Can we treat schizophrenia with it?
APA House Call: New Schizophrenia Drug Findings
APA House Call: New Schizophrenia Drug Findings
TAAR1: Trace Amine-Associated Receptor
TAAR1: Trace Amine-Associated Receptor
The efficacy and safety of SEP-363856 for Parkinson’s disease psychosis
The efficacy and safety of SEP-363856 for Parkinson’s disease psychosis
Emerging Treatment Approaches for Schizophrenia Show Promise
Emerging Treatment Approaches for Schizophrenia Show Promise
Emerging Treatments in Schizophrenia
Emerging Treatments in Schizophrenia
"Third-Generation" Antipsychotics... - Dr. Holly Gilliam Dobbins - 09/02/2022
SEP-363856: a future option for Parkinson’s disease psychosis
SEP-363856: a future option for Parkinson’s disease psychosis
Ulotaront | Neurofarmacología I
Ulotaront | Neurofarmacología I
Part 7 - Schizophrenia Education Series - Medications
Part 7 - Schizophrenia Education Series - Medications
The Risks of Youth Psychiatric Medication | In Our Heads | Episode 4 | TVO Podcast
The Risks of Youth Psychiatric Medication | In Our Heads | Episode 4 | TVO Podcast
Evidence for TAAR1 as a Potential Therapeutic Target in Psychiatric Disorders
Evidence for TAAR1 as a Potential Therapeutic Target in Psychiatric Disorders
Use of Medication
Use of Medication
Treatment options for Parkinson’s disease psychosis
Treatment options for Parkinson’s disease psychosis
Precision Medicine Leverages Organoid for Anti-Seizure Drug Therapy
Precision Medicine Leverages Organoid for Anti-Seizure Drug Therapy